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Why medical interventions are overused is unclear, but suggested factors include the preferences and expectations of health care users, 8 patient assumptions that more tests and treatments indicate superior care, payment systems that favor providing an intervention over talking with patients, defensive medicine, and the efficiency appeal of ordering a test or prescription over the time and skills required to explain why it may not be needed. 5 Current decisionmaking practices have acknowledged inadequacies, 9 and improving patients' involvement in making truly informed health decisions may improve the appropriate use of interventions.
Balancing the concerns about the overuse of interventions, at the other end of the spectrum, is underuse. Interventions with strong evidence of overall benefit can improve health outcomes only if patients commence and continue with them. Poor adherence to medical recommendations, particularly medication use, has been widely studied, with factors such as poor communication of intervention information contributing to it. 10 Underestimating the benefits and overestimating the harms of interventions may contribute to poor adherence to effective interventions. Reports of individuals' (either patients or the general public) expectations about the likely benefit or harm of various interventions are fragmented across the literature. We aimed to systematically review all studies that had quantitatively measured patient or public expectations of the benefit and/or harm of any medical treatment, test, or screen.
Methods

Types of Studies, Participants, and Outcome Measures
All quantitative primary study designs were eligible. We had no restrictions about participant eligibility. Participants could, but did not need to, be planning to receive the intervention being studied.
We included studies in which participants were asked to provide a quantitative estimate of the expected benefits and/or harms of a treatment, test, or screen (a test conducted in people without disease signs or symptoms). Outcomes were eligible if they asked about the chance of the benefit or harm occurring and/or the size of it. Studies in which participants were asked to provide a descriptive estimate without any quantification (eg, "much better," "a little worse") and those that only measured expectations about the risk of having or developing a disease or condition were excluded.
Search Methods for Identification of Studies
We used a comprehensive search strategy consisting of a combination of subject heading terms, free text words, and wild cards and proximity operators to broaden search retrieval and searched MEDLINE (1946 through June 2013), Embase (1974 through June 2013), Cumulative Index to Nursing and Allied Health Literature (1981 through June 2013), and PsycINFO (1967 through June 2013). We developed the strategy in consultation with a medical librarian experienced in systematic reviews. Initial search terms were drawn from a small set of key articles. We used an iterative process of building a search strategy, running the search, scanning the relevant retrieved articles for additional terms, and then rebuilding the search strategy with the newly identified relevant terms and related subject headings. The final search strategy for MEDLINE (eAppendix in the Supplement) was adapted for each database. To identify additional published, unpublished, and ongoing studies, we (1) tracked relevant references through Web of Science's cited reference search, (2) scanned the reference lists of identified studies, (3) contacted experts and researchers in the field, and (4) posted a request to the international evidence-based health care listserv.
Study Selection
A review author (T.C.H.) and a research assistant screened the titles and abstracts of articles identified in the searches and by other methods and eliminated articles according to the inclusion criteria. We obtained the full texts of studies considered eligible from this process or for which eligibility was unclear. A research assistant and 1 author (T.C.H.) independently decided each trial's inclusion or exclusion. We resolved any disagreements by discussion, and when consensus could not be reached, the other author (C.D.M.) was consulted and a decision made.
Data Extraction and Assessment of Methodological Quality
Both of us (T.C.H., C.D.M.) independently completed a data extraction form to extract data and record the methodological quality of studies. Disagreements were resolved by discussion. Most included studies were a survey, and accordingly we extracted information relevant to key quality criteria for assessment of bias in surveys, namely, clear research question, sufficiently large and representative sampling method, outcome measures and/or instruments used, and response rate (ideally Ն60%) 11 ( Tables 1 and 2) .
We extracted data for the outcomes and/or measures relevant to the review's purpose. For intervention studies (usually providing participants with information about the intervention being examined), we only included baseline data or, if a controlled trial, control group data. Where the authors of studies had provided a contemporaneous estimate of the benefits or harms of the intervention(s) and published this as the "correct" answer, we extracted this. For a number of studies, we contacted authors for additional data or to clarify study details.
Data Analysis
For studies that provided a correct answer about an intervention's benefits or harms, where possible, we extracted or calculated the proportion of participants who responded correctly or with an overestimation or underestimation. A meta-analysis was not possible because of the range of study designs and outcomes used. To determine patients' and parents' perceptions of risk and benefits of infliximab for IBD/ Written survey completed prior to a public lecture about IBD treatment Convenience sample of 165 patients (or parents of patients) with IBD at 1 of 2 patient education symposiums in US. 53% were adult patients (median age, 46 y); 47% were parents (median age of children, 16 y); 68% female Vignette given and asked, "If 100 similar patients with Crohn disease had the same symptoms and were treated with Remicade, how many patients out of those 100: 1. will improve in 2 wk because of the drug?" 2. will be in complete remission after 1 y of regularly taking the drug?" 
Results
Studies Identified
We screened 15 343 studies (after removing duplicates) and discarded 15 252 after examining title and abstract. Of the remaining 91 full-text articles, 36 were eligible for inclusion ( Figure 1 ), from 35 studies (2 articles were from the same study 15, 16 ).
Description of Studies
Characteristics of the studies are shown in Table 1 (studies about treatment) and Table 2 (tests and screens). In the Supplement, there is an expanded version of these tables (eTable 1 and eTable 2) that contains participants' responses to the questions about benefit and harm expectations, along with the "correct" estimate as provided by study authors. The earliest study was published in 1994, 43 and the most recent, in 2013. 47 Studies were from 16 countries, with the highest number (n = 17) from the United States. Study sample size ranged from 45 29 to 10 228. 38 Across the 35 studies, a total of 27 323 participants were involved. Across the 16 studies about treatments, there was a wide range of treatments (18) ) examined by more than 1 study. Of the 20 studies about tests or screening, 15 were concerned with cancer.
Fourteen (40%) studies focused on screening, 15 (43%) on treatment, 3 (9%) on a test, and 3 (9%) on both treatment and screening. Morestudiesassessedjustexpectationsofbenefit(22[63%])thanbenefit and harm (10 [29%]) or just harm (3 [8%] ). Across all studies, a total of 81 outcomes relevant to the review's purposes were used, with 54 outcomes assessing benefit expectations and 27 assessing harm expectations(eFigureintheSupplementshowsthisbyinterventiontopic).
Most studies used multiple-choice questions to assess expectations (69% of outcomes); the remainder asked participants to provide a quantitative estimate (eg, "out of 1000 people, how many would…") without providing response options. The most frequent study design was a survey (face-to-face, telephone, or mailed). In some studies, data were collected from patients who had received, were about to receive, or were considering receiving the intervention of interest.* In others, participants were sampled from people who were currently attending or had recently attended a health care facility 14, 18, 25, 27, 28, 33, 41, 45 or from the general population.
31,34-36, 38, 44, 46 The response rate was at least 60% in 17 of the 27 studies for which it could be determined. Three studies were randomized trials, 22,30,40 1
was a nonrandomized trial, 17 and 2 were before-and-after studies, 25, 28 in which the effect of providing information was being evaluated (only control group or baseline data for the relevant outcome were used).
Expectations of Benefit
Of the 32 studies that assessed expectations of benefit, 21 (37 outcomes) compared participants' responses with the study authors' "correct" estimates of benefit ( Figure 2 ). The majority (Ն50%) of participants overestimated benefit for 22 (65%) of the 34 outcomes for which overestimation data were provided. The proportion of participants who overestimated benefit ranged from 7% to 94%. A majority of participants provided correct estimation for only 2 outcomes: the proportion of people with improved vision after cataract surgery 15 and cervical smear test accuracy. 44 Underestimation of benefit by at least 50% of participants occurred for 1 outcome (benefit of back surgery on lower back pain). 10 Seventeen outcomes (from 15 studies) are not shown in Figure 2 because for these, either the study authors did not provide a correct estimate of benefit or outcomes were measured in a way that did not enable the proportion of patients who provided a correct answer, overestimation, or underestimation to be calculated (eg, a mean estimate of benefit; see eTables 1 and 2 in the Supplement). For 15 (88%) of these outcomes, study authors provided comment in the article that participants overestimated the benefit of the intervention(s). For 1 outcome, 22 the authors reported that the correct answer was unknown and drew no conclusion about participants' responses.
Expectations of Harm
In 11 studies (25 outcomes), harm expectations were compared with a "correct" estimate of harm; at least 50% of participants underestimated the harm for 10 (67%) 12, 15, 19, 26 ,47 of the 15 outcomes for which underestimation data were available ( Figure 3) . The proportion of participants who underestimated harm ranged from 18% to 97%. There was correct harm estimation by at least 50% of participants for only 2 outcomes: the proportion of people who still need glasses after cataract surgery 15 and miscarriage risk from amniocentesis. 37 Overestimation of harm by at least 50% of participants occurred for only 1 outcome (increased breast cancer risk from hormone therapy in healthy women). Abbreviations: CT, computed tomography; IV, intravenous; PSA, prostate-specific antigen; Q, question; QOL, quality of life; UK, United Kingdom; US, United States. a Qs also asked for "in the next 20 y," but results were not provided in the article.
b Also asked whether they thought there would be pain, radiation, and adverse effects, but quantification of risk was not assessed and data were not eligible.
ticipants correctly responding ranging from 2% to 77%. For 13 (65%) of the 20 benefit outcomes that were compared with a correct answer, benefit was overestimated by at least 50% of participants. All 6 harm outcomes were about mammography, with the proportion of correct responses ranging from 9% to 20%.
Cancer-Treatment and Risk-Reducing Surgery
Studies examined risk-reducing surgery, 2 2 , 2 3 stem cell transplantation, 20 and adjuvant chemotherapy for breast cancer.
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One measured benefit and harm expectations 20 ; 3 measured only benefit expectations. One study 22 provided the proportion of correct responses (33%, 26%), whereas the remainder 20, 23, 24 presented mean estimates of benefit and concluded that participants overestimated benefit. For the 1 harm outcome (mortality related to stem cell transplantation treatment 20 ), the majority underestimated it.
Cardiovascular Disease-Prevention and Management
Five studies (6 outcomes and 55% underestimated the risk of major complications of coronary angioplasty.
Surgery
In addition to the cardiovascular surgery studies reported in the subsection on cardiovascular disease, 3 studies (10 outcomes) assessed surgery expectations-orthopedic and eye, 15 renal transplant, 27 and bariatric surgery. 29 For the 5 benefit outcomes, 3 15 were reported as the proportion of correct responses (25%, 28%, 61%) and 2 as mean estimated benefit, 27,29 which the authors concluded were overestimates. For the 5 harm outcomes, 15 correct responses ranged from 13% to 56%, with harm underestimated by the majority for 3.
Medication
In addition to the medication studies summarized in other subsections, 17 outcomes (4 studies) measured medication expectations: infliximab for inflammatory bowel disease, 12,26 hormone therapy, 14 and medication to prevent hip fracture in osteoporosis. 18 Ten outcomes assessed benefit, with correct response rates ranging from 10% to 34% of participants and at least 50% of participants overestimating benefit in 8 outcomes. Of the 7 harm outcomes, correct response rates ranged from 2% to 37%, with harm underestimated by at least 50% of participants for 5 outcomes.
Fetal and Maternal Medicine
Of the 4 outcomes (3 studies), 2 measured benefit expectations, with a low proportion of correct responses: 9% (trial of labor after previous cesarean delivery 13 ) and 8% (fetal abnormality scan; 90% overestimated benefit of scan 32 ). Of the 2 harm outcomes, 38% (trial of labor 13 ) and 57% of participants (amniocentesis risk 37 ) provided a correct response.
Diagnostic Radiology Procedures
Expectations were measured in 2 studies 43,47 with 5 outcomes. All addressed harm, and correct responses ranged from 18% to 48%, with authors concluding that many participants underestimated harms.
Cardiopulmonary Resuscitation
Two studies (3 outcomes) assessed benefit expectations 25,48 and reported mean estimated success rates, with authors concluding that participants overestimated the success rate.
Discussion
To our knowledge, this is the first systematic review of patient or public expectations of the benefits and harms of medical interventions. Participants rarely had accurate expectations of benefits and harms, and for many interventions, regardless of whether a treatment, test, or screen, they had a tendency to overestimate its benefits and underestimate its harms. Strengths of this review include its lack of restrictions on language or study design, contact with authors for additional data, and diversity in the interventions and countries included. However, this diversity means that there is sufficient heterogeneity in the way expectations were measured to preclude calculation of summary estimates of the size of overestimates and underestimates. For some studies, we could not calculate the proportion of participants who provided correct answers, overestimates, or underestimates. In others, authors did not provide quantitative information regarding what they considered to be the correct answer yet obviously had an "answer" in mind when drawing conclusions. In studies in which authors did provide a correct estimate, we took their estimates at face value and did not attempt to verify whether these answers were based on the best evidence available at the time of that study. In at least 1 study, trial evidence 49 subsequently overturned 1 "correct" answer (hormone therapy is protective against cardiovascular disease). 14 Some studies had small and/or selective samples, and the measures used to assess participants' expectations were largely untested. The impact on expectations from asking participants at various stages of intervention consideration (not considering, considering, already received it) or from using various methods of eliciting expectations, with some questions asking about personal benefit and/or harm (eg, what are your chances…) and others about population benefit and/or harm (eg, out of 1000 people, how many…), is not clear. Overly optimistic intervention expectations by patients and the public are undoubtedly contributing to the growing problem of overdiagnosis and overtreatment. This medical optimism has many likely drivers, caused by influences within and beyond the patientclinician interaction. The relationship between optimistic bias (in which individuals perceive that they are at less risk than their peers) 50 and intervention expectations is not clear. Having unrealistic intervention expectations may enable patients to meet some psychological needs, such as hope, safety, a sense of control, action, and reassurance. 51 If patients believe that interventions are effective (which this review suggests that they largely do), they are likely to request the interventions from their clinicians. 52, 53 The point of consultation with a clinician presents an opportunity for education and correction of misperceptions about effectiveness. Yet these opportunities may be missed: clinicians are often poor at detecting expectations specific to the patient visit 54 and may avoid asking direct questions about expectations to circumvent confrontation.
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Even once clinicians are aware of patient expectations, managing them well can be difficult. A heavy impact of patient expectations and requests has been described by physicians, with approximately half of requests fulfilled only because the patient asked, despite the physicians feeling uncomfortable about some of them.
52
In a survey of US physicians, 36% indicated that they would order unnecessary investigations because of patient expectations.
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Clinicians' contributions to patients' overly optimistic expectations may range from a failure to detect and correct them to contributing (either actively or by omission) to their development or reinforcement. Clinicians themselves may have overly optimistic expectations about the benefits of interventions 57,58 and poor knowledge of harms 59 and may oversell interventions when offering them to patients. 60 Interventions may be recommended with the best of intentions-reflecting a tendency for clinicians to emphasize doing 43 1994, risk of death from contrast material rather than not doing as a habitual response to health threats and to try anything for distressed patients, however poor the evidence of effectiveness 61 or even after identifying no benefit. 58 In the absence of supporting empirical evidence, clinicians' decisions to provide an intervention may be overinfluenced by a belief in the pathophysiological effectiveness of the intervention's mechanism of action. 62, 63 Alternatively, clinicians may be unaware of the true effectiveness or benefit-harm trade-off, or there may be other influences, such as the lack of incentive for discouraging patients from proceeding with an intervention 58 or pecuniary interests, including fee-for-service.
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The sometimes misleading and inaccurate portrayal of intervention benefit in messages from many commercial sources (such as the pharmaceutical industry 65 ), health services (such as cancer centers 66 and screening services 67, 68 ) , and the media 69-72 also undoubtedly contributes to the development of overly optimistic expectations in patients and clinicians. A contributor to patients' underestimates of intervention harms may be the lack of attention given to communicating them. This is commonplace and widespreadoccurring in the media, [69] [70] [71] [72] cancer center advertisements, 66 screening invitations, 67, 68 and direct-to-consumer prescription advertising, 65 and even by clinicians. In an evaluation of what physicians in the United States tell patients about screening harms, only 9.5% of patients were informed about the possibility of overdiagnosis and overtreatment during a conversation about cancer screening, yet 80% wanted to be told of these harms before being screened. 59 Clinicians' poor knowledge of intervention harms is unsurprising because, compared with benefits, harms are much less routinely evaluated and reported in both primary research studies 73, 74 and, consequently, systematic reviews. 75 In this review's studies, two-thirds assessed only benefit expectations. Ironically, one of the influencing factors on clinicians' decisions to provide interventions (even with limited or no benefit) is patients' expectations. 52, 58, 62 In turn, because the requested interventions are often provided, patients' assumptions that they are beneficial and necessary are reinforced. 58 Breaking this positive feedback loop is crucial. Shared decision making is a logical process for achieving this. It is a process in which a clinician and patient jointly participate in making a health decision, having discussed the options and their benefits and harms and considered the patient's values, preferences, and circumstances. 76 It provides the opportunity for clinicians to elicit patients' expectations and present accurate and balanced information about the benefits and harms of each option. Evidence-informed discussions can help patients to construct informed preferences. 77 Communicating both the benefits and harms of interventions to patients may play a key role in dampening their enthusiasm for some interventions. Studies have reported that many participants indicated that they would stop, or not commence, screening if they knew that screening harms were high or outweighed the benefits. Clinicians can play a major role in facilitating less use of interventions by patients. 53 For example, they can invite patients to participate in decisions about interventions-which the majority want to do 83,84 -and ensure that they are sufficiently skilled in facilitating shared decision making and aware of resources that can assist. 76 However, shared decision making is yet to become routine
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; there are many barriers to its widespread implementation, including the need for it to be embedded in clinician training, 86 workflows and systems, and culture. 87-89 Shared decision making also provides a mechanism to overcome the failings of traditional informed consent practices, 90 to achieve truly informed consent.
Whereas overly optimistic patient expectations are undoubtedly contributing to intervention overuse, operating in the opposite direction is the possibility that overestimation of intervention benefit may be a contributor to adherence, 91 even if this is based on unfounded optimism. Hence, for interventions needed by patients on an ongoing basis, communication and decisions need to strike a delicate balance between providing accurate information about benefits and harms and avoiding compromising adherence.
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In this situation also, shared decision making, particularly for patients with chronic illnesses, can assist with achieving agreement about a treatment plan and consequently adherence.
10,93
Conclusions
The importance of this review's findings relates to the appetite that people have for medical interventions. Many want to have more and resist having less. 53, 94 Unless this is countered by accurate and balanced information, it will continue to be a driver for more intervention use than benefits society. 
